Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palbociclib for Thromboinflammation in Moderate COVID-19
NCT05371275Phase 2Withdrawn
- Sponsor
- biotx.ai
- Start
- Apr 2022
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of palbociclib in coronavirus disease 2019 (COVID-19), sponsored by biotx.ai. Primary endpoint: Rate of treatment-related treatment discontinuation after 21 days of palbociclib treatment. Planned start Apr 2022; status: withdrawn.
02
Drugs
palbociclib
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05371275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05371275.